Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoCellular Therapeutics has exclusively licensed from Cedars-Sinai Medical Center, certain novel peptides which can stimulate the immune system to target cancer stem cells in gliomas, a cancer originating in the brain or spine.
Subscribe to our email newsletter
According to the company, these peptides were specifically designed to elicit a T cell response targeting CD133 positive cancer stem cells that have been identified in a number of cancer types, including gliomas, colon cancer and pancreatic cancer.
Manish Singh, president and CEO of ImmunoCellular Therapeutics, said: “This technology allows us to leap frog to development of the next generation of cancer stem cell vaccines which could be used in an off-the-shelf manner targeting multiple cancers.”